NIH awards initial $68M for AI-driven Structure-enabled Antiviral Platform (ASAP) for open science discovery of oral antivirals for pandemic preparedness
/
We are excited to announce that the NIH has awarded an initial $68M of funding for the first three years of the AI-driven Structure-enabled Antiviral Platform (ASAP) as one of the NIAID-funded U19 Antiviral Drug Discovery (AViDD) Centers. Led by PIs John Chodera (MSKCC), Ben Perry (DNDi), and Alpha Lee (PostEra), ASAP builds on our earlier work with the COVID Moonshot, which delivered a SARS-CoV-2 oral antiviral preclinical candidate in 18 months, and will develop an open global oral antiviral pipeline with the goal of delivering medicines for globally equitable and affordable access in partnership with the Drugs for Neglected Diseases Initiative (DNDi).
